COVID-19: Coagulopathy, Risk of Thrombosis, and the Rationale for Anticoagulation
Review
Published on
Journal: Clinical and applied thrombosis/hemostasis : offic [Category] COVID-19, MERS, SARS,
Journal: Clinical and applied thrombosis/hemostasis : offic [Category] COVID-19, MERS, SARS,
[키워드] Adapted
addition
Anticoagulant
anticoagulation
bleeding event
can be used
caused
characterized
coagulation parameter
Coagulopathy
complex
COVID-19
cytokine
d -dimer
death
decrease
dosage
dose
effective
Effects
exaggerated inflammatory response
Factor
hematology
IMPROVE
incidence
increase in
Limited
LMWH
lung failure
manifestation
Microvascular thrombosis
new coronavirus SARS-CoV-2
Novel coronavirus infection
outcome
parameter
Patient
patients
patients with COVID-19
prognostic
proportion
rationale
reduction in
reported
risk
Sepsis
severe COVID-19 manifestations
severe COVID-19 patients
shown
Society
Standard dose
syndrome
thrombosis
[DOI] 10.1177/1076029620938149 PMC 바로가기 [Article Type] Review
[DOI] 10.1177/1076029620938149 PMC 바로가기 [Article Type] Review